Pathophysiology
(2 contents)
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/hub_image/public/learning-hub/2021-10/2021-09-14_NOVO_IMT2D-1-Inzucchi_550x350.png?itok=IgWJ-tKP)
Pathophysiology
Diabetes Pathophysiology
EN, ES, DE, FR
Clinical inertia
(2 contents)
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/hub_image/public/learning-hub/2021-10/Inertia.png?itok=-nqZuT_h)
Clinical inertia
Therapeutic inertia in T2DM
EN, ES, DE, FR
Incretin-based glycaemic control
(4 contents)
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/hub_image/public/learning-hub/2021-10/2021-09-14_NOVO_IMT2D-5-Davies_550x350%20%281%29.png?itok=o0iAmAPr)
Incretin-based drugs
The use of GLP-1 RAs in T2DM
EN, ES, DE, FR
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/hub_image/public/learning-hub/2021-10/2021-09-14_NOVO_IMT2D-6-Davies_550x350%20%281%29.png?itok=WJ7AWyDW)
Incretin-based drugs
Incretin-based drugs: What does the data say?
EN, ES, DE, FR
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/hub_image/public/learning-hub/2021-10/2021-09-14_NOVO_IMT2D-7-Down_550x350%20%281%29.png?itok=UwoiaUHg)
Incretin-based drugs
Incretin-based drugs: Mode of action/delivery & dosing schedule
EN, ES, DE, FR
Beyond glycaemic control
(2 contents)
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/hub_image/public/learning-hub/2021-10/2021-09-14_NOVO_IMT2D-9-Kosiborod_550x350.png?itok=9-H54tG5)
Beyond Glycaemic Control
Cardiovascular benefits
EN, ES, FR, DE